Sensorion, le début d’une belle aventure

A propos de Sensorion

https://www.sensorion-pharma.com

Sensorion est une société de biotechnologie pionnière au stade clinique dédiée au développement de thérapies géniques innovantes pour restaurer les troubles de l’audition, un important besoin médical non-satisfait.

Sensorion a développé une plateforme unique de R&D pour approfondir sa compréhension de la physiopathologie et de l’étiologie des maladies de l’oreille interne, lui permettant de sélectionner les meilleures cibles thérapeutiques et mécanismes d’action appropriés à ses candidats médicaments.

Sensorion développe dans le cadre de la mise en place d’une large collaboration stratégique ciblant la génétique de l’audition avec l’Institut Pasteur, deux programmes de thérapie génique visant à corriger les formes monogéniques héréditaires de surdité. OTOF-GT vise la surdité causée par des mutations du gène codant pour l’otoferline et GJB2-GT cible la perte auditive liée à des mutations du gène GJB2, afin de potentiellement traiter d’importants segments de perte auditive chez les adultes et les enfants. La société travaille également sur l’identification de biomarqueurs afin d’améliorer le diagnostic de ces maladies peu ou mal soignées.

Le portefeuille de Sensorion comprend également des programmes de petite molécule au stade clinique pour le traitement et la prévention des troubles de l’audition.

Son portefeuille de produits en phase clinique comprend un produit de Phase 2 : le SENS-401 (Arazasetron) qui progresse dans une étude clinique de Preuve de Concept dans l’ototoxicité induite par le cisplatine (CIO), et dans une étude en partenariat avec Cochlear Limited, chez des patients devant recevoir un implant cochléaire. Une étude de Phase 2 du SENS-401 dans la perte auditive neurosensorielle soudaine (SSNHL) a également été finalisée en janvier 2022.

Pour en savoir plus, nous vous invitons à télécharger notre dernière présentation corporate : https://www.sensorion.com/investisseurs/

About Sensorion

www.sensorion-pharma.com

Sensorion is a pioneering clinical-stage biotech company, which specializes in the development of gene therapies to restore hearing loss disorders, a significant global unmet medical need.

Sensorion has built a unique R&D technology platform to expand its understanding of the pathophysiology and etiology of inner ear related diseases, enabling it to select the best targets and mechanisms of action for drug candidates.

It has two gene therapy programs aimed at correcting hereditary monogenic forms of deafness, developed in the framework of its broad strategic collaboration focused on the genetics of hearing with the Institut Pasteur. OTOF-GT targets deafness caused by mutations of the gene encoding for otoferlin and GJB2-GT targets hearing loss related to mutations in GJB2 gene to potentially address important hearing loss segments in adults and children. The Company is also working on the identification of biomarkers to improve diagnosis of these underserved illnesses.

Sensorion’s portfolio also comprises clinical-stage small molecule programs for the treatment and prevention of hearing loss disorders.

Sensorion’s clinical-stage portfolio includes one Phase 2 product: SENS-401 (Arazasetron) progressing in a planned Phase 2 proof of concept clinical study of SENS-401 in Cisplatin-Induced Ototoxicity (CIO) and, with partner Cochlear Limited, in a study of SENS-401 in patients scheduled for cochlear implantation. A Phase 2 study of SENS-401 was also completed in Sudden Sensorineural Hearing Loss (SSNHL) in January 2022.

To learn more, please download our latest corporate presentation: Investors – Sensorion

Our values

COMMUNICATING IS KEY

We are committed to reaching out to those unheard. To constantly watch and listen to our patients’ needs. We are committed to sharing information in an honest and transparent way.

That’s how we communicate. That’s who we are.

Putting PEOPLE First

We firmly believe that what makes us human is our profound ability to provide support and care for one another in the spirit of mutual respect as fellow human beings, while remaining true to our aspirations.

That’s what defines us. That’s who we are.

FOCUSING ON PatientS

We aim to restore, treat and prevent hearing loss. We are patient focused. With a high level of integrity and trust, we aim to engage appropriately with patient communities throughout our product lifecycle.

This is how we can shape tomorrow’s healthcare standards. This is who we are.

STRIVING FOR EXCELLENCE & INNOVATION

Commitment is in our genes. Commitment to be equal to our ambitions, to go beyond the expectations of patients and healthcare communities, of regulatory authorities, as well as of our strategic partners and investors because they deserve no less. We aim to address unmet needs with unexplored solutions, means and perspectives. We strive for excellence and innovation through creativity and scientific rigor. We aim for a sustained high level of engagement and professionalism through exemplary quality, efficacy and safety. 

That’s how we work. That’s who we are.

DARING TOGETHER

“We” is our biggest strength, through transversal collaborative work practices, internal events to maintain optimal team-spirit, the high-valued external collaboration & partnerships, the top-ranked investors, the professionalism of the management team. Together, we aim to push boundaries. Together, we sometimes fail. Together, we learn and acquire wisdom. Together, we will succeed.

We’re powered by this synergy. We use our collaborative experience to ensure we challenge each other and the status quo of hearing health. That’s who we are.